# A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

> **NCT00343187** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 2 (actual)

## Conditions studied

- Rash
- Non-small-Cell Lung Cancer

## Interventions

- **DRUG:** ACZONE (dapsone) Gel, 5%
- **DRUG:** Vehicle Control

## Key facts

- **NCT ID:** NCT00343187
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2011-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343187, "A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00343187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*